
部局 大学院医学研究科

講座 医学部附属病院 臨床研究推進センター

氏名 ふりがな 真田 まいた 昌爾 しやうじ

国籍 日本

学歴	年月日	事項
1994年	3月25日	大阪大学医学部医学科 卒業
1998年	4月1日	大阪大学大学院医学系研究科情報伝達医学専攻 病態情報内科学 入学
2002年	3月25日	大阪大学大学院医学系研究科情報伝達医学専攻 病態情報内科学 修了

学位	年月日	事項
1994年	3月25日	学士(医学)(大阪大学)
2002年	3月25日	医学博士(大阪大学大学院)

免許	年月日	事項
1994年	5月6日	医師免許

認定医等	年月日	事項
1998年	9月11日	日本内科学会 認定内科医
1999年	9月28日	日本医師会 認定産業医
2005年	3月1日	日本循環器学会 認定循環器専門医
2018年	1月1日	日本臨床薬理学会 認定臨床薬理専門医
2023年	4月1日	国際臨床医学会 認定国際臨床研究者(iCRP)

職歴	年月日	事項
1994年	5月6日	大阪大学医学部 第一内科 非常勤医員(研修医)
1995年	6月1日	大阪府立病院 臨床研修部 研修医
1996年	6月1日	大阪府立病院 心臓内科 レジデント
2002年	4月1日	日本学術振興会 特別研究員(PD)
2004年	7月1日	河内総合病院 循環器科 医長
2005年	1月11日	米国ハーバード大学ブリガム&ウィメンズ病院 循環器科 フェロー
2005年	4月1日	(兼)日本学術振興会 海外特別研究員
2007年	8月1日	大阪府立急性期・総合医療センター 心臓内科 医長
2009年	4月1日	国立循環器病センター 臨床研究開発部 任意研修生
2010年	7月1日	大阪大学保健センター 助教
2012年	11月1日	大阪大学大学院医学系研究科 循環器内科学/ 医学部附属病院 未来医療開発部 特任講師(常勤)
2014年	6月1日	大阪大学大学院医学系研究科 循環器内科学/ 医学部附属病院 未来医療開発部 講師
2014年	7月1日	厚生労働省 医政局研究開発振興課 課長補佐/先進医療専門官

2016年 7月 1日 大阪大学医学部附属病院 未来医療開発部 講師
 2016年 8月 1日 大阪大学医学部附属病院 未来医療開発部
 特任准教授(常勤)
 2016年12月 1日 (兼)大学院医学系研究科・医学部附属病院 産学連携・
 クロスイノベーションイニシアティブ オフィサー
 2017年 4月 1日 (兼)大学院医学系研究科 戦略支援室 特任准教授(常勤)
 (兼)医学部附属病院 臨床試験ユニット管理部門主任
 2018年 4月 1日 (兼)医学部附属病院 未来医療開発部
 医師主導治験支援室長
 2019年 1月 1日 (兼)医学部附属病院 未来医療開発部 部長補佐
 (兼)大学院医学系研究科・医学部附属病院
 臨床研究中核病院推進支援室 特任准教授(常勤)
 (兼)医学部附属病院 未来医療開発部 先進医療支援室長
 2019年 7月 1日 大阪市立大学医学部附属病院 臨床研究・イノベーション推進
 センター 臨床研究支援部門長／特任教授
 (兼)大学院医学研究科 医療統計学 特任教授
 2020年 4月 1日 (兼)医学部附属病院 臨床研究・イノベーション推進センター
 教育研修部門長
 2020年 7月13日 (兼)医学部附属病院 臨床研究・イノベーション推進センター
 センター長補佐
 2021年 4月 1日 神戸大学医学部附属病院 臨床研究推進センター センター長
 (兼)大学院医学研究科 橋渡し科学分野長／特命教授
 2021年 4月 1日 (兼)順天堂大学 客員教授
 2021年 4月 1日 (兼)高知大学 客員教授
 現在に至る

賞 罰

2002年 大阪大学 山村賞 (最優秀医学大学院生賞)
 2002年 日本循環器学会 **C P I S賞**
 2002年 日本心臓病学会 **Y.I.A. (Young Investigator's Award)**
 2002年 **The XV Congress of the Cardiovascular System Dynamics Society
 Best Outstanding Poster Award**
 2003年 日本心臓財団 分子循環器研究助成 優秀賞
 2003年 日本循環器学会 **Y.I.A. (Young Investigator's Award)**
 2003年 成人血管病研究振興財団 岡本研究奨励賞
 2003年 日本心臓財団 「高血圧・高脂血症と血管代謝」研究助成 優秀賞
 2007年 **American Heart Association BCVS Abstract Travel Grant Award**
 2007年 日本心不全学会 臨床系 **Y.I.A. (Young Investigator's Award)**
 2008年 日本心臓財団 循環器分子細胞研究助成 優秀賞
 2008年 日本心臓財団 研究奨励賞
 2009年 日本循環器学会 **Best Reviewers of the Year 2008**
 2010年 日本循環器学会 **Best Reviewers of the Year 2009**
 2011年 日本循環器学会 **Best Reviewers of the Year 2010**
 2012年 日本循環器学会 **Best Reviewers of the Year 2011**
 2013年 日本循環器学会 **Best Reviewers of the Year 2012**
 2014年 日本循環器学会 **Best Reviewers of the Year 2013**

2014年 大阪大学 総長奨励賞
2015年 日本循環器学会 **Best Reviewers of the Year 2014**
2016年 日本循環器学会 **Best Reviewers of the Year 2015**
2017年 日本循環器学会 **Best Reviewers of the Year 2016**
2018年 日本循環器学会 **Best Reviewers of the Year 2017**
2018年 **International Heart Journal Association**
Best Reviewer Award for 2017
2019年 日本循環器学会 **Best Reviewers of the Year 2018**
2020年 日本循環器学会 **Best Reviewers of the Year 2019**
2021年 日本循環器学会 **Best Reviewers of the Year 2020**

業 績 目 録

1. 著書

No. _____

(英文：番号，著者名（掲載順に全員），著書名，発行所，発行年（西暦），頁の順に記入してください。)

(和文：番号，著書名，著者名（掲載順に全員），発行所，頁，発行年（西暦）の順に記入してください。)

(英文)

【単著】 なし

【共著】 なし

【分担執筆】

1. **Sanada S**, Kitakaze M. Ischemic Preconditioning: Accumulation of the Current Evidence of the Cellular Mechanisms and Signal Transduction. In: Recent Research Developments in Physiology. (Ed. by Gayathri A, Pandalai SG.) Research Signpost; Trivandrum, Kerala, India. 2003:179-202.
2. **Sanada S**, Kim J, Kitakaze M. Nitric Oxide and ATP-sensitive Potassium (KATP) Channel -Their Different Properties but Analogous Effects on Cardioprotection- In: Signal Transduction and the Gasotransmitters: NO, CO, and H₂S in Biology and Medicine. (Ed. by Wang R.) Humana Press; Totowa, NJ, USA. 2004:109-122.

(和文)

【単著】 なし

【共著】 なし

【分担執筆】

1. 拡張型心筋症化した非虚血性心不全と重症心室性不整脈に対しベータ遮断薬が有効であった1例，真田昌爾、福並正剛、伯耆徳武，循環器疾患 Up to Date（監修：篠山重威、堀正二、横山光宏、吉川純一），永井書店，100-102，1999.
2. 心筋梗塞，真田昌爾、北風政史，循環器領域におけるセロトニン研究の新たな展開（監修：竹下彰、横山光宏 編集：下川宏明），メジカルレビュー社，119-128，2002.
3. 胸痛，真田昌爾、北風政史、葛谷恒彦、堀正二，内科鑑別診断学 第2版（総編集：杉本恒明、小俣政男），朝倉書店，476-483，2003.
4. トピックス：Ischemic Preconditioning(基礎)，真田昌爾、北風政史，新・心臓病診療プラクティス4 冠動脈疾患を診る・I（編集：木村一雄、土師一夫），文光堂，138-141，2005.
5. 慢性心不全の病態生理，真田昌爾、山田貴久、福並正剛，重症心不全の予防と治療（編集：北風政史），中外医学社，187-195，2009.
6. 慢性心不全の病態生理，真田昌爾、山田貴久、福並正剛，カラー版 循環器病学 基礎と臨床（編集：川名正敏、北風政史、小室一成、室原豊明、山崎力、山下武志），西村書店，311-319，2010.
7. カテコラミン，真田昌爾，循環器研修ノート（編集：永井良三、川名正敏、許俊鋭、長谷川昭、廣井透雄、三田村秀雄、山下武志），診断と治療社，219-21，2010.

8. PDE阻害薬とその類似薬, 真田昌爾, 循環器研修ノート (編集: 永井良三、川名正敏、許俊鋭、長谷川昭、廣井透雄、三田村秀雄、山下武志), 診断と治療社, 225-27, 2010.
 9. 胸部X線, 真田昌爾, 診断と治療 (98巻増刊号) 初診外来における初期診療 (編集: 河邊博史、中島淳、林道夫、廣井透雄), 診断と治療社, 430-36, 2010.
 10. 筋原性酵素, 真田昌爾, 診断と治療 (98巻増刊号) 初診外来における初期診療 (編集: 河邊博史、中島淳、林道夫、廣井透雄), 診断と治療社, 479-83, 2010.
 11. 収縮不全を伴う心不全, 高濱博幸、真田昌爾, 診断と治療 (103巻増刊号) 心不全のすべて (編集: 今井靖、鈴木則宏、鈴木亮、穂苅量太), 診断と治療社, 41-46, 2015.
 12. 研究者と同じ目線に立ち、臨床研究を盛り上げたい, 真田昌爾, 22世紀の医師のリアル (編集: 西崎祐史、志水太郎、上原由紀), メジカルビュー社, 120-23, 2023
 13. 医薬品の臨床研究開発と新しい法令指針の考え方, 真田昌爾, レジデントノート (25巻増刊号) 処方「なぜ?」がわかる臨床現場の薬理学 ~蓄積した知識に新たな視点を加え、明日の診療に活かす!~ (編集: 今井靖), 羊土社, 2424-30, 2024
-

業 績 目 録

2. 論文 (原著)

No. _____

(英文：番号，著者名（掲載順に全員），論文題目，発行雑誌名，発行年（西暦），巻，頁，（IF= ， CI= ）の順に記入してください。 corresponding author(s)には，著者名の左に*を付してください。)

(和文：番号，論文題目，著者名（掲載順に全員），発行雑誌名，巻，頁，発行年（西暦）の順に記入してください。 [総説，その他も同様（IF，CIは不要）]

(英文)

1. Yamada T, *Fukunami M, Kumagai K, Abe Y, Kim J, **Sanada S**, Hori M, Kamada T, Hoki N. Detection of patients with sick sinus syndrome by use of low amplitude potentials early in filtered P wave. *J Am Coll Cardiol*. 1996 28:738-44. (IF=21.7, CI=12)
2. Abe Y, *Fukunami M, Yamada T, Ohmori M, Shimonagata T, Kumagai K, Kim J, **Sanada S**, Hori M, Hoki N. Prediction of transition to chronic atrial fibrillation in patients with paroxysmal atrial fibrillation by signal-averaged electrocardiography: a prospective study. *Circulation*. 1997;96:2612-6. (IF=35.5, CI=89)
3. Yamada T, *Fukunami M, Shimonagata T, Kumagai K, Kim J, **Sanada S**, Ogita H, Hori M, Hoki N. Prediction of the effectiveness of long-term beta blocker treatment for dilated cardiomyopathy by signal averaged electrocardiography. *Heart*. 1998;79:256-61. (IF=5.1, CI=0)
4. Minamino T, *Kitakaze M, **Sanada S**, Asanuma H, Kurotobi T, Koretsune Y, Fukunami M, Kuzuya T, Hoki N, Hori M. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. *Circulation*. 1998;98:1721-7. (IF=35.5, CI=95)
5. Yamada T, *Fukunami M, Shimonagata T, Kumagai K, **Sanada S**, Ogita H, Asano Y, Hori M, Hoki N. Dispersion of signal-averaged P wave duration on precordial body surface in patients with paroxysmal atrial fibrillation. *Eur Heart J*. 1999;20:211-20. (IF=37.6, CI=63)
6. *Kitakaze M, Asanuma H, Takashima S, Minamino T, Ueda Y, Sakata Y, Asakura M, **Sanada S**, Kuzuya T, Hori M. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. *Circulation*. 2000;101:311-7. (IF=35.5, CI=56)
7. *Kitakaze M, Node K, Asanuma H, Takashima S, Sakata Y, Asakura M, **Sanada S**, Shinozaki Y, Mori H, Kuzuya T, Hori M. Protein Tyrosine Kinase Is Not Involved in the Infarct Size-limiting Effect of Ischemic Preconditioning in Canine Hearts. *Circ Res*. 2000;87:303-8. (IF=16.5, CI=13)
8. **Sanada S**, *Kitakaze M, Papst PJ, Hatanaka K, Asanuma H, Aki T, Shinozaki Y, Ogita H, Node K, Takashima S, Asakura M, Kuzuya T, Mori H, Terada N, Yoshida Ki, Hori M. Role of Phasic Dynamism of P38 Mitogen-activated Protein Kinase Activation in the Ischemic Preconditioning on the Canine Heart. *Circ Res*. 2001;88:175-80. (IF=16.5, CI=88)

9. **Sanada S**, *Kitakaze M, Asanuma H, Papst PJ, Node K, Liao Y, Shinozaki Y, Ogita H, Takashima S, Sakata Y, Asakura M, Kuzuya T, Terada N, Mori H, Hori M. Cardioprotective Effect Afforded by Transient Exposure to Phosphodiesterase-III Inhibitors. –The Role of Protein Kinase A and P38 Mitogen-activated Protein Kinase– **Circulation**. 2001;104:705-10. (IF=35.5, CI=93)
10. **Sanada S**, *Kitakaze M, Asanuma H, Harada K, Ogita H, Node K, Takashima S, Sakata Y, Asakura M, Shinozaki Y, Mori H, Kuzuya T, Hori M. Role of the Mitochondrial and Sarcolemmal KATP Channels in Ischemic Preconditioning on the Canine Heart. **Am J Physiol Heart Circ Physiol**. 2001;280:H256-63. (IF=4.1, CI=73)
11. **Sanada S**, *Kitakaze M, Node K, Takashima S, Ogai A, Asanuma H, Sakata Y, Asakura M, Ogita H, Liao Y, Fukushima T, Yamada J, Minamino T, Kuzuya T, Hori M. Differential Subcellular Actions of ACE Inhibitors and AT₁ Blockers on Cardiac Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis in Rats. **Hypertension**. 2001;38:404-11. (IF=6.9, CI=44)
12. *Kitakaze M, Node K, Takashima S, Asanuma H, Asakura M, **Sanada S**, Shinozaki Y, Mori H, Sato H, Kuzuya T, Hori M. Role of cellular acidosis in production of nitric oxide in canine ischemic myocardium. **J Mol Cell Cardiol**. 2001;33:1727-37. (IF=4.9, CI=21)
13. Asanuma H, *Kitakaze M, Funaya H, Takashima S, Minamino T, Node K, Sakata Y, Asakura M, **Sanada S**, Shinozaki Y, Mori H, Kuzuya T, Hori M. Nifedipine Limits Infarct Size via NO-dependent Mechanisms In Dogs. **Basic Res Cardiol**. 2001;96:497-505. (IF=7.5, CI=17)
14. *Kitakaze M, Asakura M, Sakata Y, Asanuma H, **Sanada S**, Kuzuya T, Miyazaki J, Takashima S, Hori M. cDNA Array Hybridization Reveals Cardiac Gene Expression in Acute Ischemic Murine Hearts. **Cardiovasc Drugs Ther**. 2001;15:125-30. (IF=3.1, CI=7)
15. Asanuma H, *Kitakaze M, Node K, Takashima S, Sakata Y, Asakura M, **Sanada S**, Shinozaki Y, Mori H, Tada M, Kuzuya T, Hori M. Benidipine, a Long-acting Ca Channel Blocker, Limits Infarct Size via NO-dependent Mechanisms In Dogs. **Cardiovasc Drugs Ther**. 2001;15:225-31. (IF=3.1, CI=15)
16. Asakura M, Kitakaze M, *Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, **Sanada S**, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, *Higashiyama S. Cardiac Hypertrophy is Inhibited by Antagonism of ADAM12 Processing of HB-EGF: Metalloproteinase Inhibitors as a Potential New Therapy for Cardiac Hypertrophy. **Nat Med**. 2002;8:35-40. (IF=58.7, CI=618)
17. *Takashima S, Kitakaze M, Asakura M, Asanuma H, **Sanada S**, Tashiro F, Niwa H, Miyazaki J, Hirota S, Kitamura Y, Kitsukawa T, Fujisawa H, Klagsbrun M, Hori M. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. **Proc Natl Acad Sci U S A**. 2002;99:3657-62. (IF=9.4, CI=269)
18. Asakura M, *Kitakaze M, Sakata Y, Asanuma H, **Sanada S**, Kim J, Ogita H, Liao Y, Node K, Takashima S, Tada M, Hori M. Adenosine-induced cardiac gene expression of ischemic murine

- hearts revealed by cDNA Array Hybridization. *Circ J*. 2002;66:93-6. (IF=3.1, CI=4)
19. Liao Y, Ishikura F, Beppu S, Asakura M, Takashima S, Asanuma H, **Sanada S**, Kim J, Ogita H, Kuzuya T, Node K, *Kitakaze M, Hori M. Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. *Am J Physiol Heart Circ Physiol*. 2002;282:H1703-8. (IF=4.1, CI=117)
 20. *Kitakaze M, Asanuma H, Funaya H, Node K, Takashima S, **Sanada S**, Asakura M, Ogita H, Kim J, Hori M. ACE inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: Role of bradykinin. *J Am Coll Cardiol*. 2002;40:162-6. (IF=21.7, CI=20)
 21. **Sanada S**, Node K, Asanuma H, Ogita H, Takashima S, Minamino T, Asakura M, Liao Y, Ogai A, Kim J, Hori M, *Kitakaze M. Opening of ATP-sensitive Potassium Channel Attenuates Cardiac Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis –Role of 70kDa S6 Kinase and Extracellular Signal-regulated Kinase – *J Am Coll Cardiol*. 2002;40:991-7. (IF=21.7, CI=32)
 22. Ogita H, *Node K, Asanuma H, **Sanada S**, Liao Y, Takashima S, Asakura M, Mori H, Shinozaki Y, Hori M, Kitakaze M. Amelioration of Ischemia- and Reperfusion-induced Myocardial Injury by the Selective Estrogen Receptor Modulator, Raloxifene, in the Canine Heart. *J Am Coll Cardiol*. 2002;40:998-1005. (IF=21.7, CI=33)
 23. Asanuma H, *Node K, Minamino T, **Sanada S**, Takashima S, Ueda Y, Sakata Y, Asakura M, Kim J, Ogita H, Tada M, Hori M, Kitakaze M. Celiprolol, Increases Coronary Blood Flow and Reduces the Severity of Myocardial Ischemia via Nitric Oxide Release. *J Cardiovasc Pharmacol*. 2003;41:499-505. (IF=2.6, CI=13)
 24. **Sanada S**, Node K, Minamino T, Takashima S, Asakura M, Liao Y, Asanuma H, Ogita H, Ogai A, Kim J, Hori M, *Kitakaze M. Long Acting Ca²⁺ Blockers Prevent Myocardial Remodeling Induced by Chronic NO Inhibition in Rats. *Hypertension*. 2003;41:963-7. (IF=6.9, CI=61)
 25. Ogita H, *Node K, Asanuma H, **Sanada S**, Takashima S, Minamino T, Soma M, Kim J, Hori M, Kitakaze M. Eicosapentaenoic Acid Reduces Myocardial Injury Induced by Ischemia and Reperfusion in Rabbit Hearts. *J Cardiovasc Pharmacol*. 2003;41:964-9. (IF=2.6, CI=27)
 26. Asakura M, Takashima S, Asano Y, Honma T, Asanuma H, **Sanada S**, Shintani Y, Liao Y, Kim J, Ogita H, Node K, Minamino T, Yorikane R, Ogai A, Kitamura H, Tomoike H, Hori M, *Kitakaze M. Canine DNA array as a potential tool to combine the physiology to molecular biology: An application for gene expression profile of regional ischemic myocardium. *Circ J*. 2003;67:788-92. (IF=3.1, CI=7)
 27. Liao Y, *Takashima S, Asano Y, Asakura M, Ogai A, Shintani Y, Minamino T, Asanuma H, **Sanada S**, Kim J, Ogita H, Tomoike H, Hori M, Kitakaze M. Activation of Adenosine A1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine LV Pressure Overload Model. *Circ Res*. 2003;93:759-66. (IF=16.5, CI=110)

28. Ogita H, *Node K, Liao Y, Ishikura F, Beppu S, Asanuma H, **Sanada S**, Takashima S, Minamino T, Hori M, Kitakaze M. Raloxifene Prevents Cardiac Hypertrophy and Dysfunction in Pressure-Overloaded Mice. *Hypertension*. 2004;43:237-42. (IF=6.9, CI=36)
29. Asano Y, *Takashima S, Asakura M, Shintani Y, Liao Y, Minamino T, Asanuma H, **Sanada S**, Kim J, Ogai A, Fukushima T, Oikawa Y, Okazaki Y, Kaneda Y, Sato M, Miyazaki J, Kitamura S, Tomoike H, Kitakaze M, Hori M. Lamr1-functional retroposon causes right ventricular dysplasia in mice. *Nat Genet*. 2004;36:123-30. (IF=31.7, CI=43)
30. Asanuma H, **Sanada S**, Ogai A, Minamino T, Takashima S, Asakura M, Ogita H, Shinozaki Y, Mori H, Node K, Tomoike H, Hori M, *Kitakaze M. Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts. *J Cardiovasc Pharmacol*. 2004;43:574-9. (IF=2.6, CI=30)
31. Ogita H, *Node K, Asanuma H, **Sanada S**, Kim J, Takashima S, Minamino T, Hori M, Kitakaze M. Raloxifene Improves Coronary Perfusion, Cardiac Contractility and Myocardial Metabolism in the Ischemic Heart: Role of Phosphatidylinositol 3-Kinase/Akt Pathway. *J Cardiovasc Pharmacol*. 2004;43:821-9. (IF=2.6, CI=20)
32. Asanuma H, *Minamino T, **Sanada S**, Takashima S, Ogita H, Ogai A, Asakura M, Liao Y, Asano Y, Shintani Y, Kim J, Shinozaki Y, Mori H, Node K, Kitamura S, Tomoike H, Hori M, Kitakaze M. The β -Adrenoceptor Blocker, Carvedilol Provides Cardioprotection via Adenosine-dependent Mechanism in Ischemic Canine Hearts. *Circulation*. 2004;109:2773-9. (IF=35.5, CI=36)
33. **Sanada S**, Asanuma H, Tsukamoto O, Minamino T, Node K, Takashima S, Fukushima T, Ogai A, Shinozaki Y, Fujita M, Hirata A, Okuda H, Shimokawa H, Tomoike H, Hori M, *Kitakaze M. Protein Kinase A as Another Mediator of Ischemic Preconditioning Independent of Protein Kinase C. *Circulation*. 2004;110:51-7. (IF=35.5, CI=88)
34. Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Shintani Y, Minamino T, Asanuma H, **Sanada S**, Kim J, Kitamura S, Tomoike H, Hori M, *Kitakaze M. A Vasodilatory β -Blocker, Celiprolol, Inhibits Pressure Overload-induced Cardiac Hypertrophy and Prevents the Transition to Heart Failure via NO-dependent Mechanisms in Mice. *Circulation*. 2004;110:692-9. (IF=35.5, CI=54)
35. **Sanada S**, Asanuma H, Minamino T, Node K, Takashima S, Okuda H, Shinozaki Y, Ogai A, Asano Y, Fujita M, Hirata A, Kim J, Mori H, Tomoike H, Kitamura S, Hori M, *Kitakaze M. Optimal Windows of Statin Use for Immediate Infarct-limitation: 5'-Nucleotidase as Another Downstream Molecule of Phosphatidylinositol-3 Kinase. *Circulation*. 2004;110:2143-9. (IF=35.5, CI=78)
36. Shintani Y, *Node K, Asanuma H, **Sanada S**, Takashima S, Asano Y, Liao Y, Fujita M, Hirata A, Shinozaki Y, Fukushima T, Nagamachi Y, Okuda H, Kim J, Tomoike H, Hori M, Kitakaze M. The Opening of Ca²⁺-activated K⁺ Channels is Involved in Ischemic Preconditioning in Canine Hearts. *J Mol Cell Cardiol*. 2004;37:1213-8. (IF=4.9, CI=61)

37. Fujita M, *Minamino M, **Sanada S**, Asanuma H, Hirata A, Ogita H, Okada Ki, Tsukamoto O, Takashima S, Tomoike H, Node K, Hori M, Kitakaze M. Selective Blockade of Serotonin 5HT_{2A} Receptor Increases Coronary Blood Flow via Augmented Cardiac Nitric Oxide Release Through 5HT_{1B} Receptor in Hypoperfused Canine Hearts. **J Mol Cell Cardiol.** 2004;37:1219-23. (IF=4.9, CI=31)
38. Li Y, *Minamino T, Tsukamoto O, Yujiri T, Shintani Y, Okada Ki, Nagamachi Y, Fujita M, Hirata A, **Sanada S**, Asanuma H, Takashima S, Hori M, Johnson GL, Kitakaze M. Ablation of MEK Kinase 1 Suppresses Intimal Hyperplasia by Impairing Smooth Muscle Cell Migration and Urokinase Plasminogen Activator Expression in a Mouse Blood-Flow Cessation Model. **Circulation.** 2005;111:1672-8. (IF=35.5, CI=11)
39. Hirata A, *Minamino T, Asanuma H, **Sanada S**, Fujita M, Tsukamoto O, Wakeno M, Myoishi M, Okada K, Koyama H, Komamura K, Takashima S, Shinozaki Y, Mori H, Tomoike H, Hori M, Kitakaze M. Erythropoietin Just Before Reperfusion Reduces Both Lethal Arrhythmias and Infarct Size via the Phosphatidylinositol-3 Kinase-Dependent Pathway in Canine Hearts. **Cardiovasc Drugs Ther.** 2005;19:33-40. (IF=3.1, CI=74)
40. Fujita M, *Minamino T, Asanuma H, **Sanada S**, Hirata A, Wakeno M, Myoishi M, Okuda H, Ogai A, Okada Ki, Tsukamoto O, Koyama H, Hori M, Kitakaze M. Aldosterone Nongenomically Worsens Ischemia via PKC-dependent Pathways in Hypoperfused Canine Hearts. **Hypertension.** 2005;46:113-7. (IF=6.9, CI=46)
41. Asanuma H, Minamino T, **Sanada S**, Ogita H, Kim J, Fujita M, Hirata A, Tsukamoto O, Ogai A, Node K, Tomoike H, *Kitakaze M. A Calcium Channel Blocker Amlodipine Increases Coronary Blood Flow via both Adenosine- and NO-dependent Mechanisms in Ischemic Hearts. **J Mol Cell Cardiol.** 2005;39:605-14. (IF=4.9, CI=4)
42. Tsukamoto O, *Minamino T, **Sanada S**, Okada K, Hirata A, Fujita M, Shintani Y, Liao Y, Asano Y, Takashima S, Yamasaki S, Tomoike H, Hori M, Kitakaze M. The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. **Cardiovasc Drugs Ther.** 2006;20:93-102. (IF=3.1, CI=14)
43. Asanuma H, Minamino T, Ogai A, Kim J, Asakura M, Komamura K, **Sanada S**, Fujita M, Hirata A, Wakeno M, Tsukamoto O, Shinozaki Y, Myoishi M, Takashima S, Tomoike H, *Kitakaze M. Blockade of Histamine H₂ Receptors Protects the Heart against Ischemia and Reperfusion Injury in Dogs. **J Mol Cell Cardiol.** 2006;40:666-74. (IF=4.9, CI=24)
44. Asanuma H, Nakai K, **Sanada S**, Minamino T, Takashima S, Ogita H, Fujita M, Hirata A, Wakeno M, Kim J, Asakura M, Sakuma I, Kitabatake A, Hori M, Komamura K, *Kitakaze M. S-nitrosylated and pegylated hemoglobin, a newly developed artificial oxygen carrier, exerts cardioprotection against ischemic hearts. **J Mol Cell Cardiol.** 2007;42:924-30. (IF=4.9, CI=16)
- ④5. **Sanada S**, Asanuma H, Koretsune Y, Watanabe K, Nanto S, Awata N, Hoki N, Fukunami M, *Kitakaze M, Hori M. A Long-term Oral Administration of Dipyridamole Improves both Cardiac

and Physical Status in Patients with Mild to Moderate Chronic Heart Failure: A Prospective Open-randomized Study. *Hypertens Res.* 2007;30:913-9. (IF=4.3, CI=18)

- 46) **Sanada S**, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, *Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. *J Clin Invest.* 2007;117:1538-49. (IF=13.3, CI=812)
47. Masuda M, Yamada T, Okuyama Y, Morita T, **Sanada S**, Furukawa Y, Tsukamoto Y, Okuda K, Iwasaki Y, Yasui T, *Fukunami M. Sodium bicarbonate improves long-term clinical outcomes compared with sodium chloride in patients with chronic kidney disease undergoing an emergent coronary procedure. *Circ J.* 2008;72:1610-4. (IF=3.1, CI=17)
48. Fujita M, Asakura M, **Sanada S**, Funaya H, Komamura K, Tsukamoto O, Taketani S, Isomura T, Furukawa H, Sawa Y, Hori M, *Kitakaze M. Activation of Ecto-5'-nucleotidase in the Blood and Hearts in Patients with Chronic Heart Failure. *J Card Fail.* 2008;14:426-30. (IF=6.7, CI=7)
49. Tamaki S, Yamada T, Okuyama Y, Morita T, **Sanada S**, Tsukamoto Y, Masuda M, Okuda K, Iwasaki Y, Yasui T, Hori M, *Fukunami M. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. *J Am Coll Cardiol.* 2009;53:426-35. (IF=21.7, CI=174)
50. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Itou S, Ogai A, Asakura M, Kim J, Minamino T, Takashima S, **Sanada S**, Sugimachi M, Komamura K, Mochizuki N, *Kitakaze M. Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-activated Protein Kinase. *Circulation.* 2009;119:2568-77. (IF=35.5, CI=264)
51. *Kato M, **Sanada S**, Kitakaze M. Should we use outpatient dobutamine or milrinone? *Circ Heart Fail.* 2009;2:377-8. (IF=7.8, CI=2)
- 52) Seki K, **Sanada S**, Kudinova AY, Steinhauser ML, Handa V, Gannon J, *Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. *Circ Heart Fail.* 2009;2:684-91. (IF=7.8, CI=290)
53. Min KD, *Asakura M, Liao Y, Nakamaru K, Okazaki H, Takahashi T, Fujimoto K, Ito S, Takahashi A, Asanuma H, Yamasaki S, Minamino T, **Sanada S**, Seguchi O, Nakano A, Ando Y, Otsuka T, Furukawa H, Isomura T, Takashima S, Mochizuki N, Kitakaze M. Identification of Genes related to Heart Failure Using Global Gene Expression Profiling of Human Failing Myocardium. *Biochem Biophys Res Commun.* 2010;393:55-60. (IF=2.5, CI=85)
54. Sawada T, *Minamino T, Fu HY, Asai M, Okuda K, Isomura T, Yamazaki S, Asano Y, Okada KI, Tsukamoto O, **Sanada S**, Asanuma H, Asakura M, Takashima S, Kitakaze M, Komuro I. X-box binding protein 1 regulates brain natriuretic peptide through a novel AP1/CRE-like element in cardiomyocytes. *J Mol Cell Cardiol.* 2010;48:1280-9. (IF=4.9, CI=54)

55. Fu HY, Okada Ki, Liao Y, Tsukamoto O, Isomura T, Asai M, Sawada T, Okuda K, Asano Y, **Sanada S**, Asanuma H, Asakura M, Takashima S, Komuro I, Kitakaze M, *Minamino T. Ablation of C/EBP homologous protein attenuates ER-mediated apoptosis and cardiac dysfunction induced by pressure overload. **Circulation**. 2010;122:361-369. (IF=35.5, CI=221)
56. Higo S, Asano Y, Kato H, Yamazaki S, Nakano A, Tsukamoto O, Seguchi O, Asai M, Asakura M, Asanuma H, **Sanada S**, Minamino T, Komuro I, Kitakaze M, Takashima S. Isoform-specific intermolecular disulfide bond formation of heterochromatin protein 1 (HP1). **J Biol Chem**. 2010;285:31337-47. (IF=4.0, CI=4)
57. Takahama H, Asanuma H, **Sanada S**, Fujita M, Sasaki H, Wakeno M, Kim J, Asakura M, Takashima S, Minamino T, Komamura K, Sugimachi M, Kitakaze M. A Histamine H2 Receptor Blocker Ameliorates Development of Heart Failure in Dogs Independently of Adrenergic Receptor Blockade. **Basic Res Cardiol**. 2010;105:787-94. (IF=7.5, CI=35)
58. Sohma R, Inoue T, Abe S, Taguchi I, Kikuchi M, Toyoda S, Arikawa T, Hikichi Y, **Sanada S**, Asanuma H, Kitakaze M, Node K. Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. **J Cardiol**. 2012;59:91-6. (IF=2.5, CI=7)
59. ***Sanada S**, Asanuma H, Minamino T, Tsukamoto O, Okada K, Kitakaze M, Komuro I. Repetitive transient phosphodiesterase-3 inhibition eliminates non-ischemic cardiac remodeling and failure. **Immunol Endocr Metab Agents Med Chem**. 2012;7:130-136. (IF=0, CI=1)
60. Yoshida A, Asanuma H, Sasaki H, **Sanada S**, Yamazaki S, Asano Y, Shinozaki Y, Mori H, Shimouchi A, Sano M, Asakura M, *Minamino T, Takashima S, Sugimachi M, Mochizuki N, Kitakaze M. H(2) Mediates Cardioprotection Via Involvements of K(ATP) Channels and Permeability Transition Pores of Mitochondria in Dogs. **Cardiovasc Drugs Ther**. 2012;26:217-26. (IF=3.1, CI=42)
61. **Sanada S**, Nishida M, Ishii K, Moriyama T, Komuro I, *Yamauchi-Takahara K. Smoking promotes subclinical atherosclerosis in apparent healthy men -Two years ultrasonographic follow-up- **Circ J**. 2012;76:2884-91. (IF=3.1, CI=17)
62. Takahama H, Shigematsu H, Asai T, Matsuzaki T, **Sanada S**, Hai-Ying Fu, Okuda K, Yamato M, Asanuma H, Asano Y, Asakura M, Oku N, Komuro I, Kitakaze M, *Minamino T. Liposomal Amiodarone Augments Anti-arrhythmic Effects and Reduces Hemodynamic Adverse Effects in an Ischemia/Reperfusion Rat Model. **Cardiovasc Drugs Ther**. 2013;27:125-32. (IF=3.1, CI=30)
63. Takahashi A, *Asakura M, Ito S, Min KD, Shindo K, Yan Y, Liao Y, Yamazaki S, **Sanada S**, Asano Y, Ishibashi-Ueda H, Takashima S, Minamino T, Asanuma H, Mochizuki N, Kitakaze M. Dipeptidyl-Peptidase IV Inhibition Improves Pathophysiology of Heart Failure and Increases Survival Rate in Pressure-Overloaded Mice. **Am J Physiol Heart Circ Physiol**. 2013;304:H1361-9. (IF=4.1, CI=54)
64. Asanuma H, **Sanada S**, Asakura M, Asano Y, Kim J, Shinozaki Y, Mori H, Minamino T,

- Takashima S, *Kitakaze M. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO. *Hypertens Res.* 2014;37:716-23. (IF=4.3, CI=8)
65. Fu HY, Sanada S, Matsuzaki T, Liao Y, Okuda K, Yamato M, Tsuchida S, Araki R, Asano Y, Asanuma H, Asakura M, French BA, Sakata Y, Kitakaze M, *Minamino T. A Chemical Endoplasmic Reticulum Chaperone Alleviates Doxorubicin-induced Cardiac Dysfunction. *Circ Res.* 2016;118:798-809. (IF=16.5, CI=84)
66. Ito S, *Asakura M, Liao Y, Min KD, Takahashi A, Shindo K, Yamazaki S, Tsukamoto O, Asanuma H, Mogi M, Horiuchi M, Asano Y, Sanada S, Minamino T, Takashima S, Mochizuki N, Kitakaze M. Identification of the Mtus1 Splice Variant as a Novel Inhibitory Factor against Cardiac Hypertrophy. *J Am Heart Assoc.* 2016;5 pii:e003521. (IF=5.0, CI=10)
67. Okuda K, Fu HY, Matsuzaki T, Araki R, Tsuchida S, Thanikachalam PV, Fukuta T, Asai T, Yamato M, Sanada S, Asanuma H, Asano Y, Asakura M, Hanawa H, Hao H, Oku N, Takashima S, Kitakaze M, Sakata Y, *Minamino T. Targeted therapy for acute autoimmune myocarditis with nano-sized liposomal FK506 in rats. *PLoS One* 2016;11(8):e0160944. (IF=2.9, CI=12)
68. Yamato M, Matsuzaki T, Araki R, Tsuchida S, Okuda K, Fu HY, Sanada S, Asanuma H, Asano Y, Asakura M, Torii H, Noi K, Ogi H, Iwamoto R, Mekada E, Takashima S, Kitakaze M, Sakata Y, *Minamino T. RNA Aptamer Binds Heparin-Binding Epidermal Growth Factor-Like Growth Factor with High Affinity and Specificity and Neutralizes Its Activity. *Int J Gerontol.* 2017;11:191-96. (IF=0.3, CI=0)
69. Thanikachalam PV, *Sanada S, Okuda K, Fu HY, Matsuzaki T, Araki R, Yamato M, Yasuda K, Sakata Y, Yoshimoto T, Minamino T. Ablation IL-33 gene Exacerbate Myocardial Remodeling in Mice with Heart Failure Induced by Mechanical Stress. *Biochem Pharmacol.* 2017;138:73-80. (IF=5.3, CI=49)
70. Asanuma H, Sanada S, Yoshitomi T, Sasaki H, Takahama H, Ihara M, Takahama, H, Shinozaki Y, Mori H, Asakura M, Nakano A, Sugimachi M, Asano Y, Minamino T, Takashima S, *Nagasaki Y, *Kitakaze M. Novel Synthesized Radical-Containing Nanoparticles Limits Infarct Size Following Ischemia and Reperfusion in Canine Heart. *Cardiovasc Drugs Ther.* 2017;31:501-510. (IF=3.1, CI=19)
71. Araki R, Matsuzaki T, Nakamura A, Nakatani D, Sanada S, Fu HY, Okuda K, Yamato M, Tsuchida S, Sakata Y, *Minamino T. Development of a novel one-step production system for injectable liposomes under GMP. *Pharm Dev Technol.* 2018;23:602-607. (IF=2.6, CI=9)
72. Tsuchida S, Matsuzaki T, Yamato M, Okuda K, Fu HY, Araki R, Sanada S, Asanuma H, Asano Y, Asakura M, Hao H, Takashima S, Kitakaze M, Sakata Y, Mekada E, *Minamino T. Anti-HB-EGF antibody-mediated delivery of siRNA to atherosclerotic lesions in mice. *Int Heart J.* 2018;59:1425-31. (IF=1.2, CI=3)
73. *Mizuno A, Kishi T, Matsumoto C, Kawai F, Ishida M, Sanada S, Hokimoto S, Saito Y, Yamauchi-Takahara K, Komuro I, Node K. The potential role of Twitter at an annual congress

- Japan. -narrative literature review of "Tweet the Meeting"- **Circ Rep.** 2019;1:401-4. (IF=0, CI=0)
74. Ueda R, *Nishizaki Y, Homma Y, Sanada S, Otsuka T, Yasuno S, Matsuyama K, Yanagisawa N, Nagao M, Fujibayashi K, Nojiri S, Seo Y, Yamada N, Devos P, Daida H. Importance of quality assessment in clinical research in Japan. **Front Pharmacol.** 2019;10:1228. (IF=4.4, CI=8)
75. Sugimoto T, *Mizuno A, Kishi T, Ito N, Matsumoto C, Fukuda M, Kagiya N, Shibata T, Ohmori T, Oishi S, Fuse J, Kida K, Kawai F, Ishida M, Sanada S, Komuro I, Node K. Coronavirus disease 2019 (COVID-19) information for cardiologists -systematic literature review and additional analysis- **Circ J.** 2020;84:1039-43. (IF=3.1, CI=16)
76. *Ueda K, Sanada S, Uemura N. Advanced Medical Care Programme for the rapid introduction of health care technologies to the National Health Insurance system in Japan. **Clin Transl Sci.** 2020;13:700-706. (IF=3.1, CI=2)
77. *Kishi T, Mizuno A, Ishida M, Matsumoto C, Fukuda M, Sanada S, Ito N, Oka H, Node K, Komuro I. Recommendations for Maintaining the Cardiovascular Care System under the COVID-19 Pandemic -1st Edition at April 2020- **Circ J.** 2020;84:2023-26. (IF=3.1, CI=5)
78. *Mizuno A, Kishi T, Matsumoto C, Ishida M, Sanada S, Fukuda M, Sahashi Y, Sugimoto T, Hirano M, Yoshikawa Y, Yamamoto E, Kimura T, Node K. Two-year experience in "Tweeting the meeting" during the Scientific Sessions. **Circ Rep.** 2020;2:691-94. (IF=0, CI=0)
79. *Nishizaki Y, Homma Y, Ueda R, Devos P, Sanada S. Differences in author ranking: Development of SIGAPS scoring system for Japanese version. **J Gen Fam Med.** 2020;21:208-9. (IF=0, CI=2)
80. *Ueda K, Uemura N, Matsuyama K, Nishizaki Y, Tanemura N, Asano K, Otsuka Y, Yanagisawa N, Otsuka T, Yasuno S, Ueda R, Seo Y, Nakagami H, Sanada S. Performance Index for Types of Clinical Research Support Service Providers for Academic Research Organizations in Japan: A Cross-Sectional Survey, **Clin Transl Sci.** 2021;14:745-55. (IF=3.1, CI=1)
81. Tamaki S, *Yamada T, Watanabe T, Morita T, Furukawa Y, Kawasaki M, Kikuchi M, Kawai T, Seo M, Abe M, Nakamura J, Yamamoto K, Kayama K, Kawahira M, Tanabe K, Fujikawa K, Hata M, Fujita Y, Umayahara Y, Taniuchi S, Sanada S, Shintani A, Fukunami M. Effect of Empagliflozin as an Add-on Therapy on Decongestion and Renal Function in Diabetic Patients Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study. **Circ Heart Fail.** 2021;14:e007048. (IF=7.8, CI=43)
82. *Mizuno A, Matsumoto C, Yoneoka D, Kishi T, Ishida M, Sanada S, Fukuda M, Saito Y, Yamauchi-Takahara K, Tsutsui H, Fukuda K, Komuro I, Node K. Cardiology department practices in the first wave of the COVID pandemic: a nationwide survey in Japan by the Japanese Circulation Society. **Circ Rep.** 2021;3:137-41. (IF=0, CI=0)
83. *Mizuno A, Matsumoto C, Kishi T, Ishida M, Sanada S, Fukuda M, Komuro I, Hirata Ki, Node K.

Cardiology department policy in Japan -Descriptive summary of 2nd nationwide survey by Japanese Circulation Society- **Circ Rep.** 2021;3:100-104. (IF=0, CI=0)

84. * Mizuno A, Rewley J, Kishi T, Matsumoto C, Sahashi Y, Ishida M, **Sanada S**, Fukuda M, Sugimoto T, Hirano M, Node K. Relationship Between Official Twitter Ambassadors and the Number of Retweets in the Annual Congress - “Tweet the Meeting” - **Circ Rep.** 2021;3:414-18. (IF=0, CI=0)
85. Ueda R, * Nishizaki Y, Nojiri S, Iwata H, Miyauchi K, Matsuyama K, **Sanada S**, Minamino T, Daida H. Factors Associated With the Acceleration of Patient Enrollment in Clinical Studies: A Cross-Sectional Study. *Front Pharmacol.* **Front Pharmacol.** 2021;12:753067. (IF=4.4, CI=3)
86. * Mizuno A, Kusunose K, Kishi T, Rewley J, Matsumoto C, Sahashi Y, Ishida M, **Sanada S**, Fukuda M, Sugimoto T, Hirano M, Sata M, Anzai T, Node K. The impact of tweeting summary by the Japanese Circulation Society official account on the article viewership -pilot trial- **Circ J.** 2022;86:715-20. (IF=3.1, CI=3)
87. * Nishizaki Y, Ueda R, Nojiri S, **Sanada S**. Clinical Research Support Activities in Core Clinical Research Hospitals Throughout Japan **Juntendo Med J.** 2022;68:413-15. (IF=0, CI=0)
88. Morisawa F, * Nishizaki Y, Devos P, Yanagisawa N, Matsuyama K, Homma Y, Ueda R, Sekine M, Daida H, Minamino T, **Sanada S**. The association between research funding status and clinical research papers' citation impact in Japan: A cross-sectional bibliometric study. **Front Med.** 2022;9:978174. (IF=3.1, CI=3)
89. Sekine M, Kataoka K, * Nishizaki Y, Matsuyama K, Otsuka T, Sato K, Idei M, **Sanada S**. A cross-sectional survey on principal investigators' clinical research knowledge in Japan. **Clin Transl Sci.** 2023;16:459-66. (IF=3.1, CI=0)
90. * Ikka T, Fujita M, Hatta T, Isobe T, Konomi K, Onishi T, **Sanada S**, Sato Y, Tashiro S, Tobita M. Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan **Stem Cell Rep.** 2023;18:613-17. (IF=5,9, CI=3)
91. Sekine M, Kiyama Y, Ueda R, Aune D, **Sanada S**, * Nishizaki Y. Understanding international norms regarding academic authorship bylines in general medicine. **Juntendo Med J.** 2023;69:405-8. (IF=0, CI=0)
92. Suzuki T, * Mizuno A, Kishi T, Rewley J, Matsumoto C, Sahashi Y, Ishida M, **Sanada S**, Fukuda M, Sugimoto T, Hirano M, Node K. Relationship Between the Contents of Tweets and the Number of Retweets - “Tweet the Meeting” **Circ Rep.** 2023;5:306-10. (IF=0, CI=0)
93. Nakagawa S, Kowa H, Takagi Y, Kakei Y, Kagimura T, **Sanada S**, Nagai Y. Efficacy of a non-pharmaceutical multimodal intervention program in a group setting for patients with mild cognitive impairment: A single-arm interventional study with pre-post and external control analyses. **Contemp Clin Trials Commun.** 2024 Jun 14;40:101326. (IF=1.4, CI=0)

94. * Mizuno A, Yoneoka D, Kishi T, Kusunose K, Matsumoto C, Sahashi Y, Ishida M, **Sanada S**, Fukuda M, Sugimoto T, Hirano M, Sata M, Anzai T, Node K. From Optional to Default: Enhancing Article Viewership through X (formerly Twitter) Posting. **Circ Rep.** 2024 Aug ;6:389-394. (IF=0, CI=0)
95. Fujimoto Y, Fujita Y, Tanaka K, Nagashima H, Yamanishi S, Ikeuchi Y, Iwahashi H, **Sanada S**, Muragaki Y, * Sasayama T. Clinical benefits of photodynamic therapy using talaporfin sodium in patients with IDH-wild newly diagnosed glioblastoma. **Neurosurgery.** (In Press) (IF=3.9, CI=0)

(和文)

1. ATP 感受性K⁺チャンネルによる心筋梗塞縮小効果：分子メカニズムの検討， *北風政史、**真田昌爾**、浅沼博司、野出孝一、南野哲男、高島成二、中條光章、盛英三、葛谷恒彦、堀正二， **Jpn J Electrocardiology.** 19 卷, 161-169, 1999
 2. プレコンディショニングの分子メカニズム-細胞膜・ミトコンドリア ATP 感受性K⁺チャンネル開口による虚血プレコンディショニングの心筋保護作用， *北風政史、**真田昌爾**、浅沼博司、野出孝一、高島成二、南野哲男、中條光章、篠崎芳郎、盛英三、葛谷恒彦、堀正二， **自律神経.** 37 卷, 349-356, 2000
 3. 虚血プレコンディショニングの分子メカニズムの解明-細胞膜・ミトコンドリア ATP 感受性K⁺チャンネル開口による相加的心筋梗塞サイズ縮小効果， *北風政史、**真田昌爾**、浅沼博司、野出孝一、南野哲男、高島成二、中條光章、篠崎芳郎、盛英三、葛谷恒彦、堀正二， **Jpn J Electrocardiology.** 20 卷, 103-111, 2000
 4. 細胞膜/ミトコンドリア ATP 感受性K⁺チャンネルは相加的に心筋梗塞サイズ縮小効果を発揮する-麻酔開胸犬での検討-， ***真田昌爾**、北風政史、浅沼博司、扇田久和、葛谷恒彦、篠崎芳郎、盛英三、堀正二， **Ther. Res.** 21 卷, 785-789, 2000
 5. アデノシンと心筋保護-プレコンディショニングとの関わり， ***真田昌爾**、北風政史、浅沼博司、南野哲男、野出孝一、高島成二、朝倉正紀、扇田久和、葛谷恒彦、堀正二， **Jpn J Applied Physiol.** 31 卷, 73-78, 2001
 6. ニコランジル長期投与により、NO 欠乏による慢性心不全が血圧非依存性に抑制される-K_{ATP} チャンネル開口が P70S6K と ERK に及ぼす影響-， ***真田昌爾**、北風政史、南野哲男、野出孝一、浅沼博司、坂田泰彦、朝倉正紀、扇田久和、葛谷恒彦、堀正二， **Ther. Res.** 22 卷, 708-711, 2001
 7. 臨床研究法で定義される「研究・開発支援担当者」及び「調整管理実務担当者」のコア・コンピテンシー・モデルの開発に関する研究， *岩崎幸司、今野浩一、菊地佳代子、大塚佑基、松山琴音、秦友美、**真田昌爾**， **Jpn Pharmacol. Ther.** 48 卷, s65-s80, 2020
 8. 多職種協調型ワークショップの成果物としてのプロトコル素案作成に関する考察 *大谷直由、塩崎正幸、久本佳奈、水城史貴、荒木浩之、田尻涼、稲田実枝子、肥田典子、有田悦子、**真田昌爾**， **臨床薬理** 52 卷, 165-174, 2021
-

業績目録

3. 論文 (総説)

No. _____

(英文)

1. **Sanada S**, Kitakaze M. Ischemic Preconditioning: Emerging Evidence, Controversy and Translational Trials. *Int J Cardiol.* 2004;97:263-76.
2. **Sanada S**, Komuro I, Kitakaze M. Pathophysiology of Myocardial Reperfusion Injury: Preconditioning, Postconditioning and Translational Aspects of Protective Measures. *Am J Physiol Heart Circ Physiol.* 2011;301:H1723-41.
3. Matsushita S, Tachibana K, Nakai K, **Sanada S**, Kondoh M. A review of the regulatory framework for initiation and acceleration of patient access to innovative medical products in Japan. *Clin Pharmacol Ther.* 2019;106:508-11.
4. Ota N, Tachibana K, Kusakabe T, **Sanada S**, Kondoh M. A concept for a Japanese regulatory framework for emerging medical devices with frequently modified behavior. *Clin Transl Sci.* 2020;13:877-879.

(和文)

1. 心疾患における至適降圧薬選択, 真田昌爾、北風政史、葛谷恒彦、堀正二, 血圧, 5巻, 1027-1033, 1998.
2. アデノシンと冠循環—最近の進歩, 北風政史、真田昌爾、葛谷恒彦、堀正二, 血管と内皮, 8巻, 566-574, 1998
3. 硝酸薬の特性とその使用にあたって 真田昌爾、北風政史, 循環科学, 19巻, 56-58, 1999.
4. 胸痛, 真田昌爾、北風政史、葛谷恒彦、堀正二, 老年医学, 37巻 259-261, 1999
5. 心不全と硝酸薬, 真田昌爾、北風政史、葛谷恒彦、堀正二, 医薬ジャーナル, 35巻, 2240-2247, 1999.
6. 虚血性心疾患とプレコンディショニング, 北風政史、真田昌爾, *Molecular Medicine*. (臨時増刊号 生活習慣病の分子メカニズムと治療), 259-264, 2001.
7. 虚血プレコンディショニングの現況, 北風政史、真田昌爾、堀正二, 医学のあゆみ. (別冊: 循環器疾患 State of Arts 2), 81-84, 2001.
8. 虚血プレコンディショニング, 真田昌爾、北風政史, 血管医学, 3巻, 79-87, 2002.
9. ATP依存性Kチャンネル開口が慢性NO産生阻害ラットの心臓リモデリングを抑制する—70kDa S6 Kinase と Extracellular Signal-regulated Kinase の役割—, 真田昌爾、野出孝一、浅沼博司、高島成二、南野哲男、朝倉正紀、堀正二、北風政史, *J Cardiol.* 41巻, 43-44, 2003.
10. 再灌流障害の機序に関する研究の動向, 真田昌爾、野出孝一、北風政史、堀正二, 日本臨床. 61巻(Supple4), 135-141, 2003.

11. ACE-I・ARB・抗アルドステロン薬, 真田昌爾、北風政史, 日本臨床. 61 巻, 821-826, 2003.
12. プレコンディショニングによる心筋の保護, 真田昌爾、北風政史, IHD Frontier. 4 巻, 51-56, 2003.
13. プレコンディショニング, 北風政史、真田昌爾, 内科 (内科キーワード 6 月増大号), 91 巻, 1188, 2003.
14. 心臓とスタチン, 真田昌爾、北風政史, 呼吸と循環. 51 巻, 787-793, 2003.
15. 虚血プレコンディショニングによる心筋保護の分子メカニズムと臨床展開, 真田昌爾、北風政史, 循環器科. 54 巻, 3-10, 2003.
16. 冠末梢循環内因性保護因子とその活性化 北風政史、真田昌爾, Coronary Intervention., 2 巻, 385, 2003.
17. 強心薬に心保護効果があるか, 真田昌爾、北風政史, 呼吸と循環. 52 巻, 891-896, 2004.
18. Ischemic Preconditioning と虚血耐性, 北風政史、真田昌爾, Medicina. 42 巻, 2086-2088, 2005.
19. Long-term Oral Administration of Dipyridamole Improves both Cardiac and Physical Status in Patients with Mild to Moderate Chronic Heart Failure: A Prospective Open-randomized Study, 真田昌爾, 分子心血管病, 9 巻, 297-299, 2008.
20. 心筋虚血再灌流障害をレビューする～原因解明と治療への試み～, 真田昌爾, 日本臨床麻酔学会誌. 30 巻, 40-51, 2010.
21. 新しいストレス応答性転写抑制サイトカインによる心筋リモデリング抑止機構の解明と心不全治療への応用, 真田昌爾, かなえ医薬振興財団助成金受賞者研究業績集, 37 巻, 24-31, 2010.
22. Ischemic Pre/Postconditioning—薬物治療への応用—, 真田昌爾、北風政史, ICU とCCU. 35 巻, 463-468, 2011.
23. 心臓弁膜症に関連した心不全に対する薬物治療, 高濱博幸、真田昌爾, 内科, 116 巻, 463-466, 2015.
24. 先進医療・再生医療に係る制度の概要, 真田昌爾, 循環器内科, 80 巻, 328-335, 2016.
25. 眼科における先進医療について, 真田昌爾, あたらしい眼科, 34 巻, 1501-08, 2017.
26. 適応未承認のロボット支援下手術に対する薬事承認・保険収載に向けた課題と戦略, 真田昌爾, 頭頸部癌, 43 巻, 307-10, 2017.
27. 先進医療, 真田昌爾, カレントセラピー, 36 巻, 486-486, 2018.

28. 産婦人科領域の先進医療, 真田昌爾, 産科と婦人科, 36 巻, 57-62, 2018.
 29. 先進医療・患者申出療養などの保険外併用療養費制度, 真田昌爾, 循環器内科, 87 巻, 520-25, 2020.
 30. 先進医療・患者申出療養などの保険外併用療養とその周辺制度, 真田昌爾, 整形外科 (5 月増刊号「整形外科臨床研究の手引き」), 71 巻, 636-40, 2020.
 31. 再生医療等安全性確保法への対応, 笹井雅夫、真田昌爾, Precision Medicine, 3 巻, 619-22, 2020.
 32. 多職種共同臨床研究計画ワークショップ ～開発までの流れとその概要～, 真田昌爾, Jpn Pharmacol Ther. (特集「第 22 回 CRC と臨床試験のあり方を考える会議 2022 in 新潟」) 52 巻, 120-3, 2024
-

業 績 目 録

4. 論文 (その他)

No. _____

(英文)

1. Blann AD, Li-Saw-Hee F, Lip GY, Minamino T, Kitakaze M, **Sanada S**, Asanuma H, Kurotobi T, Koretsune Y, Fukunami M, Kuzuya T, Hoki N, Hori M. Increased membrane and soluble P-selectin in atrial fibrillation. **Circulation**. 1999;100:e86-7.
2. **Sanada S**, Kitakaze M. Combined Renin-angiotensin system-inhibition therapy -What really accounts for the additive benefits?- **Circ J**. 2010;74:2288-9
3. **Sanada S**, Komuro I. Costarring statins with ARBs - Going to be a smash hit? - **Circ J**. 2011;75:540-1.
4. **Sanada S**, Kitakaze M, Komuro I. The less embraces the greater in detecting multiple coronary artery diseases. **Circ J**. 2012;76:299-300.
5. **Sanada S**. Finding the Optimal Regulatory Systems to Facilitate the Development of Novel and Advanced Therapeutics. **Circ Rep**. 2019;1:43-45.
6. Kishi T, Hirano T, Mizuno A, Matsumoto C, Fukuda M, **Sanada S**, Ishida M, Node K, Miyamoto S, Komuro I, Directors of the Japan Stroke and Japanese Circulation Societies. Joint declaration on COVID-19 by the Japan Stroke and Japanese Circulation Societies. **Circ Rep**. 2020;2:343-44.
7. Nishizaki Y, Homma Y, Ueda R, Devos P, **Sanada S**. Differences in author ranking: Development of SIGAPS scoring system for Japanese version. **J Gen Fam Med**. 2020;21:208-9.
8. Ueda R, Nishizaki Y, Homma Y, Devos P, **Sanada S**. The relationship between contributions of authors and author order. **J Gen Fam Med**. 2021;22:361-2.

(和文)

なし

業 績 目 録

5. 学会発表（国内学会） No. _____
（番号，演題名，発表者（共同発表者を含む），学会名，発行年の順に記入してください。）
-

【特別講演・教育講演】

1. Opening of ATP-sensitive Potassium Channel Attenuates Cardiac Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis – Role of 70kDa S6 Kinase and Extracellular Signal-regulated Kinase – **Sanada S**, Node K, Asanuma H, Takashima S, Minamino T, Asakura M, Hori M, Kitakaze M. JCC 50th Annual Scientific Sessions (2002年 名古屋) – *Young Investigator's Award* – **J Cardiol.** 2003;41:43-44.
2. Preischemic Protein Kinase-A Activation Evokes Ischemic Preconditioning Through Rho-Kinase Inhibition Independent of Protein Kinase-C – A Novel Mechanism – **Sanada S**, Node K, Asanuma H, Ogita H, Kim J, Minamino T, Takashima S, Asakura M, Ogai A, Shimokawa H, Hori M, Kitakaze M. JCS 67th Annual Scientific Sessions (2003年 福岡) – *Young Investigator's Award* – **Circ J.** 2003;67(Supple I):87.
3. PDE 阻害薬の細胞内心筋保護シグナル～プレコンディショニングの新展開，**真田昌爾**，第 8 回日本心臓血管麻酔学会総会イブニングセミナー（2003年 奈良）
4. 21 世紀における慢性心不全治療の新展開 心筋保護・免疫調節の立場から～アデノシン～，**真田昌爾**，第 52 回 日本心臓病学会総会ファイアースайдセミナー（2004年 京都）
5. PDE-III 阻害薬が導くプレコンディショニングの未来，**真田昌爾**，第 53 回日本麻酔科学会総会ランチョンセミナー（2006年 神戸）
6. 心臓虚血再灌流障害をレビューする，**真田昌爾**，第 28 回日本臨床麻酔学会総会ランチョンセミナー（2008年 京都）
7. 先進医療の出口戦略について ～薬事承認の更に向こう側～，**真田昌爾**，第 37 回日本臨床薬理学会学術総会教育講演（2016年 鳥取（米子））
8. 患者申出療養とその周辺関連制度，**真田昌爾**，第 2 回日本臨床薬理学会近畿地方会教育講演（2017年 大阪）
9. 臨床開発と評価療養～先進医療の出口戦略など～，**真田昌爾**，第 41 回日本眼科手術学会学術総会インストラクションコース（2018年 京都）

【シンポジウム】

1. Cross-talk of Adenosine and KATP Channels in Ischemic Preconditioning. **Sanada S**, Kitakaze M, Kuzuya T, Hori M. ISHR 16th Meetings, Japanese Section (1999年 福岡) **J Mol Cell Cardiol.** 1999;31:A165.
2. Role of Adenosine in chronic heart failure: the possibility for novel therapeutic strategies. Kitakaze M, Asakura M, Asanuma H, **Sanada S**, Takashima S, Node K, Kuzuya T, Hori M. JCC 48th Annual Scientific Sessions (2000年 大阪) **J Cardiol.** 2000;39:80

3. Role of P38 Mitogen-activated Protein Kinase in the Infarct-limiting Effect of Ischemic Preconditioning. **Sanada S**, Kitakaze M, Node K, Takashima S, Asanuma H, Asakura M, Kuzuya T, Hori M. ISHR 18th Meetings, Japanese Section (2001年 秋田)
4. Role of P38 Mitogen-activated Protein Kinase in the Infarct Size-limiting Effect of Ischemic Preconditioning in Vivo. Kitakaze M, **Sanada S**, Takashima S, Node K, Asanuma H, Asakura M, Kuzuya T, Hori M. JCS 65th Annual Scientific Sessions (2001年 京都)
5. Data Mining of the Best Treatments of Chronic Heart Failure and Proposal of Adenosine Therapy as a New Treatment. Kitakaze M, Kim J, Yasumura Y, Asakura M, Asanuma H, **Sanada S**, Takashima S, Nakamaru K, Furukawa H, Isomura T, Miyatake K, Tomoike H, Hori M, Kitamura S. JCS 67th Annual Scientific Sessions (2003年 福岡) **Circ J.** 2003;67(Suppl I):41.
6. Immediate Cardioprotection Against Acute Coronary Syndrome and the Super-acute Effect of Statins: Role of Adenosine. **Sanada S**, Node K, Minamino T, Asanuma H, Kim J, Fujita M, Hori M, Kitakaze M. JCC 51st Annual Scientific Sessions (2003年 東京) **J Cardiol.** 2003;42(Suppl 1):101.
7. ST2 is an emerging functional biomarker predicting mortality after acute heart events and comprising stress-induced cardioprotective signaling system with IL-33. **Sanada S**, Kitakaze M, Lee RT. JCS 73rd Annual Scientific Sessions (2009年 大阪) **Circ J.**2009;73(Suppl I):25.
8. Prevention of Subclinical Atherosclerosis: Search for Gender-specific Risk Factors and Salutary Interventions Against its Progression. **Sanada S**, Nishida M, Ohama T, Komuro I, Yamauchi-Takahara K. JCS 76th Annual Scientific Sessions (2012年 福岡) **Circ J.** 2012;76(Suppl I): 242.
9. Smoking Duration Governs Subclinical Atherosclerotic Progression Stronger than Duration of Smoking Cessation in Apparent Healthy Men: Two Years Ultrasonographic Follow-up, **Sanada S**, Nishida M, Komuro I, Yamauchi-Takahara K. JCS 77th Annual Scientific Sessions (2013年 横浜) **Circ J.** 2013;77(Suppl I).
10. ハートが老いるということ ～加齢か？疾病か？～, **真田昌爾**, 第14回日本抗加齢医学会総会プレゼンポジウム (2014年 大阪)
11. 本邦の循環器領域における先進医療の状況, **真田昌爾**, 第18回日本心不全学会学術集会シンポジウム (2014年 大阪)
12. 先進医療の状況と利用戦略, **真田昌爾**, 第24回日本臨床精神神経薬理学会・第44回日本神経精神薬理学会合同年会シンポジウム (2014年 名古屋)
13. ベンチからクリニックへのロードマップと問題点, **真田昌爾**, 第77回日本耳鼻咽喉科臨床学会総会・学術講演会シンポジウム (2015年 浜松)
14. 新しい医療を形にする戦略, **真田昌爾**, 第21回日本遺伝子治療学会学術集会若手企画シンポジウム (2015年 大阪)

15. ロボット支援内視鏡手術保険収載へのロードマップ, 真田昌爾, 第28回日本内視鏡外科学会総会 シンポジウム (2015年 大阪)
16. 先進医療制度について, 真田昌爾, 第24回日本血管生物医学会学術集会シンポジウム (2016年 長崎)
17. 先進医療の出口戦略について, 真田昌爾, 第41回日本頭頸部癌学会シンポジウム (2017年 京都)
18. 臨床研究を推進するための規制科学からみた臨床薬理専門医の必要性, 真田昌爾, 第38回日本臨床薬理学会学術総会シンポジウム (2017年 横浜)
19. Efforts on Creating Index of Medical Service System for Acute Coronary Syndrome and Acute Aortic Syndrome to Construct Desirable System. Sakata Y, Isobe M, Yasuda S, Miyamoto Y, Nishimura K, Nakamura F, Saito Y, Imamura T, Hirayama A, Tsujita K, Nakao K, Morino S, Ueda Y, Takayama M, Sanada S, Hikoso S, Komuro I. JCS 82nd Annual Scientific Sessions (2018年 大阪) *Circ J*. 2018;82(Supple I).
20. 考えられる特定の職能 (4) 新しい医療の評価=研究開発計画支援者, 真田昌爾, 第40回日本臨床薬理学会学術総会シンポジウム (2019年 東京)

【パネルディスカッション】

1. Probability of EDHF as an anti-atherosclerotic agent. Node K, Kitakaze M, Asanuma H, Sanada S, Ogita H, Takashima S, Asakura M, Hori M. JCC 49th Annual Scientific Sessions (2001年 広島) *J Cardiol*. 2001;40:95.
2. Percutaneous intrarenal artery ablation for the treatment of resistant essential hypertension using conventional 5 Fr cardiac ablation catheter. Okuyama Y, Nakatani D, Minamiguchi H, Kanzaki M, Masuda M, Sanada S, Minamino T, Sakata, Y, Komuro I, Nanto S. The Japanese Association of Cardiovascular Intervention and Therapeutics 22nd Annual Scientific Sessions (2013年 神戸)
3. 耳科領域先端技術の実用化へのロードマップと課題, 真田昌爾, 第25回日本耳科学会総会・学術講演会パネルディスカッション (2015年 長崎)

【プレナリーセッション・ラウンドテーブルディスカッション・その他】

1. A novel therapeutic strategy against cardiac failure based on cardioprotective mechanisms of preconditioning: brief phosphodiesterase-3 inhibition and transient PKA activation. Sanada S, Kitakaze M. JCS 74th Annual Scientific Sessions (2010年 京都) —*Round-table Discussion*— *Circ J*. 2010;74(Supple I):73.
2. Cardiac Hypertrophy is Inhibited by Antagonism of Metalloproteinase Processing of HB-EGF. Takashima S, Kitakaze M, Asakura M, Asanuma M, Sanada S, Hori M. JCS 78th Annual Scientific Sessions (2014年 東京) —*Plenary Session*— *Circ J*. 2014;78(Supple I).

3. Academic Drug Development for Treatment of Acute Myocardial Infarction Using Nano-sized Liposomes. Minamino T, Matsuzaki T, **Sanada S**, Yao XJ, Sawa Y. JCS 78th Annual Scientific Sessions (2014年 東京) –*Plenary Session*– *Circ J.* 2014;78 (Supple I).
 4. 循環器・腎臓・高血圧領域の先進医療の状況, **真田昌爾** 第37回日本高血圧学会総会ワークショップ (2014年 横浜)
 5. **Sanada S**. Translational Research as Investigator-initiated Phase I/IIa Clinical Trials -A Perspective on Japan-, JCS 81st Congress (2017年 金沢) –*Round Table Discussion*–
 6. 診療と研究の境界、臨床研究法のエッセンスについて, **真田昌爾**, 第20回日本抗加齢医学会総会倫理・利益相反ワークショップ (2020年 東京)
-

業 績 目 録

6. 学会発表（国際会議） No. _____
（番号，演題名，発表者（共同発表者を含む），学会名，発行年の順に記入してください。）

【特別講演】

1. The Selective Estrogen Receptor Modulator, Raloxifene, Improves the Severity of Myocardial Ischemia in Canine Hearts. Ogita H, Kitakaze M, Node K, Takashima S, Asanuma H, Asakura M, **Sanada S**, Asano Y, Shintani Y, Hori M. 51st Annual Scientific Sessions (2002, Atlanta) – *Young Investigator's Award* – **J Am Coll Cardiol**. 2002;39(Suppl A):442A.

【シンポジウム】

1. Pharmacological Preconditioning: Current Investigations on the Mechanisms and Clinical Applications. **Sanada S**, Kitakaze M. The International Symposium for Cardiac Anesthesia (2003, Morioka, Japan)
2. A new TLR Family Member that Predicts Cardiac Mortality and Comprises Stress-induced Cardioprotective Signaling. **Sanada S**, Komuro I, Kitakaze M. The 8th Korea-Japan Joint Symposium on Vascular Biology. (2010, Osaka, Japan)
3. Translational Research as Investigator-initiated Phase I/IIa Clinical Trials -A Perspective on Japan. **Sanada S**. The 81th Annual Meeting of the Japanese Circulation Society (2017, Kanazawa, Japan)

【その他受賞演題】

1. Inhalation of hydrogen gas reduced infarct size following ischemia and reperfusion in dogs. Yoshida A, Asanuma H, Sasaki H, **Sanada S**, Yamazaki S, Asakura M, Kitakaze M. ISHR 20th World Congress (2010, Kyoto, Japan) – *Best Poster Award* – **J Mol Cell Cardiol**. 2010.
2. Opening of ATP-sensitive Potassium Channel Attenuates Cardiac Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis –Role of 70kDa S6 Kinase and Extracellular Signal-regulated Kinase–, **Sanada S**, Node K, Liao Y, Takashima S, Minamino T, Asakura M, Hori M, Kitakaze M. The 15th International Congress of The Cardiovascular System Dynamics Society (2002, Sendai, Japan) – *Best Outstanding Poster Award* –
3. Inhalation of hydrogen gas reduced infarct size following ischemia and reperfusion in dogs. Yoshida A, Asanuma H, Sasaki H, **Sanada S**, Yamazaki S, Asakura M, Kitakaze M. The 20th World Congress of The International Society for Heart Research (2010, Kyoto, Japan) – *Best Poster Award* – **J Mol Cell Cardiol**. 2010.

【一般演題】

1. Detection of patients with sick sinus syndrome at risk for Stokes-Adams attacks by use of the P wave-triggered signal-averaged ECG. Yamada T, Fukunami M, Shimonagata T, Kumagai K, Abe Y, Kim J, Sanada S, Hoki N. The American Heart Association 69th Scientific Sessions (1996, New Orleans), **Circulation**. 1996;94(Suppl 1):I-373.

2. Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure by P wave signal-averaged ECG: a prospective study. Yamada T, Fukunami M, Shimonagata T, Kumagai K, **Sanada S**, Ogita H, Asano Y, Hoki N. The American Heart Association 69th Scientific Sessions (1996, New Orleans), **Circulation**. 1996;94(Suppl 1):I-441.
3. Anatomical basis of QT dispersion in patients with dilated cardiomyopathy. Yamada T, Fukunami M, Shimonagata T, Kumagai K, **Sanada S**, Ogita H, Asano Y. The American Heart Association 69th Scientific Sessions (1996, New Orleans), **Circulation**. 1996;94(Suppl 1):I-441.
4. Dispersion of atrial depolarization in patients with paroxysmal atrial fibrillation by body surface mapping of P wave-triggered signal-averaged electrocardiography. Yamada T, Fukunami M, Shimonagata T, Kumagai K, Abe Y, Kim J, **Sanada S**, Hoki N. The American Heart Association 69th Scientific Sessions (1996, New Orleans), **Circulation**. 1996;94(Suppl 1):I-447.
5. Does spectral turbulence abnormality of the signal-averaged ECG reflect cardiac sympathetic nerve dysfunction in patients with chronic heart failure?, Kim J, Fukunami M, Shimonagata T, Yamada T, **Sanada S**, Hoki N. The American Heart Association 70th Scientific Sessions (1997, Orlando), **Circulation**. 1997;96(Suppl 1):I-651.
6. The involvement of apoptosis in a variety of diseases which cause left ventricular dysfunction, **Sanada S**, Fukunami M, Shimonagata T, Kumagai K, Yamada T, Kim J, Ohgita H, Hoki N. The American College of Cardiology 46th Annual Scientific Sessions (1997, Anaheim), **J Am Coll Cardiol**. 1997;29(Suppl A):504A.
7. Prognostic significance of cardiac adrenergic nerve activity state in patients with chronic heart failure: a prospective study using cardiac 123-metaiodobenzylguanidine imaging. Ogita H, Fukunami M, Shimonagata T, Yamada T, **Sanada S**, Asano Y, Hoki N. The American Heart Association 70th Scientific Sessions (1998, Dallas), **Circulation**. 1998;98(Suppl 1):I-278.
8. Detection of patients at risk for paroxysmal atrial fibrillation improved by body surface mapping of P wave signal-averaged ECG, Yamada T, Fukunami M, Shimonagata T, Kumagai K, **Sanada S**, Ohgita H, Asano Y, Hoki N. The American College of Cardiology 47th Annual Scientific Sessions (1998, Atlanta), **J Am Coll Cardiol**. 1998;31(Suppl A):47A.
9. Prediction of efficacy of pilsicainide to paroxysmal atrial fibrillation by body surface mapping of the P wave signal-averaged ECG: a prospective study, Yamada T, Fukunami M, Shimonagata T, Kumagai K, **Sanada S**, Ohgita H, Asano Y, Hoki N. The American College of Cardiology 47th Annual Scientific Sessions (1998, Atlanta), **J Am Coll Cardiol**. 1998;31(Suppl A):47A.
10. Apoptosis of myocardial cell is associated with the abnormal signal-averaged ECG in patients with idiopathic dilated cardiomyopathy. Yamada T, Fukunami M, Shimonagata T, Kumagai K, **Sanada S**, Ohgita H, Asano Y, Hoki N. The American College of Cardiology 47th Annual Scientific Sessions (1998, Atlanta), **J Am Coll Cardiol**. 1998;31(Suppl A):266A.
11. Prediction of the effectiveness of long-term beta-blocker therapy for dilated cardiomyopathy by signal-averaged electrocardiography: a prospective study. Yamada T, Fukunami M, Shimonagata T,

Kumagai K, **Sanada S**, Ohgita H, Asano Y, Hoki N. The American College of Cardiology 47th Annual Scientific Sessions (1998, Atlanta), **J Am Coll Cardiol.** 1998;31(Suppl A):266A.

12. Dobutamine induced late potential are related to the residual myocardial viability after acute myocardial infarction with reperfusion therapy. The American College of Cardiology 47th Annual Scientific Sessions (1998, Atlanta), Yamada T, Fukunami M, Shimonagata T, Kumagai K, **Sanada S**, Ohgita H, Asano Y, Hoki N. **J Am Coll Cardiol.** 1998;31(Suppl A):447A.
13. Transient exposure to nicotine mediates the infarct size-limiting effect via activation of ecto-5'-nucleotidase. Role of alpha(1)-adrenoceptor activation. Asanuma H, **Sanada S**, Mori H, Shinozaki Y, Kuzuya T. The American Heart Association 72nd Scientific Sessions (1999, Atlanta), **Circulation.** 1999;100(Suppl 1):I-424.
14. Inhibition of p38 mitogen-activated protein kinase blunts the infarct size-limiting effect of ischemic preconditioning in the in vivo canine heart. **Sanada S**, Takashima S, Sakata Y, Asakura M, Terada N. The American Heart Association 72nd Scientific Sessions (1999, Atlanta), **Circulation.** 1999;100(Suppl 1):I-492.
15. Both sarcolemmal and mitochondrial ATP-sensitive potassium channels synergically mimic the infarct size-limiting effect of ischemic preconditioning in the canine heart. **Sanada S**, Takashima S, Harada K, Shinozaki Y, Mori H, Kitakaze M. The American Heart Association 72nd Scientific Sessions (1999, Atlanta), **Circulation.** 1999;100(Suppl 1):I-717.
16. A Role of Activation of P38 Mitogen-activated Protein Kinase Followed by HSP27 Translocation in the Infarct Size-limiting Effect of Ischemic Preconditioning in Vivo Canine Heart. **Sanada S**, Papst PJ, Hatanaka K, Shinozaki Y, Node K, Kim J, Mori H, Terada N, Yoshida Ki, Hori M. The American Heart Association 73rd Scientific Sessions (2000, New Orleans), **Circulation.** 2000;102:II-212.
17. Endothelium-Derived Hyperpolarized Factor Activates Peroxisome Proliferator-Activated Receptors Alpha and Beta but not Gamma. Node K, Sakata Y, **Sanada S**. The American Heart Association 73rd Scientific Sessions (2000, New Orleans), **Circulation.** 2000;102:II-305.
18. Carvedilol limits Infarct size via adenosine-dependent mechanisms In dogs. Asanuma H, Kitakaze M, **Sanada S**, Takashima S, Sakata Y, Asakura M, Kuzuya T, Hori M. The American College of Cardiology 49th Annual Scientific Sessions (2000, Anaheim), **J Am Coll Cardiol.** 2000;35(Suppl A):350A.
19. Transient exposure of nicotine attenuates the severity of canine myocardial stunning via α 1-adrenergic receptor activation and augmentation of ecto-5'-nucleotidase activity. **Sanada S**, Kitakaze M, Asanuma H, Ogita H, Harada K, Takashima S, Sakata Y, Asakura M, Kuzuya T, Hori M. The American College of Cardiology 49th Annual Scientific Sessions (2000, Anaheim), **J Am Coll Cardiol.** 2000;35(Suppl A): 369A.
20. MX-68, a new delivative of methotrexate, limits Infarct size via adenosine-dependent mechanisms In dogs. Asanuma H, Kitakaze M, **Sanada S**, Takashima S, Sakata Y, Asakura M, Kuzuya T, Hori M. The American College of Cardiology 49th Annual Scientific Sessions (2000, Anaheim), **J Am Coll**

Cardiol. 2000;35(Suppl A): 370A.

21. The effects of Ischemic preconditioning on adenosine deaminase and kinase activities In the canine heart. Kitakaze M, Asanuma H, **Sanada S**, Takashima S, Ueda Y, Sakata Y, Asakura M, Ogita H, Kuzuya T, Hori M. The American College of Cardiology 49th Annual Scientific Sessions (2000, Anaheim), **J Am Coll Cardiol.** 2000;35(Suppl A): 401A.
22. Transient Pretreatment With Phosphodiesterase-III inhibitors Limits Infarct Size via PKA-dependent but PKC-independent Mechanism. **Sanada S**, Kitakaze M, Asanuma H, Ogita H, Node K, Asakura M, Sakata Y, Liao Y, Kuzuya T, Hori M. ISHR 17th Meetings, Japanese Section (2000, Osaka, Japan), **J Mol Cell Cardiol.** 2000;32:A97.
23. HB-EGF is involved in Pathway of Cardiac Hypertrophy. Asakura M, Kitakaze M, Takashima S, Node K, Sakata Y, Asanuma H, **Sanada S**, Higashiyama S, Kuzuya T, Tada M, Hori M. ISHR 17th Meetings, Japanese Section (2000, Osaka, Japan), **J Mol Cell Cardiol.** 2000;32:A91.
24. A Possible Role of Neuropilin 2 Expression in the Development of Early Embryonic Vascular Network and Neurovascular Junction. Takashima S, Asakura M, **Sanada S**, Asanuma H, Kitakaze M, Kuzuya T, Hori M. ISHR 17th Meetings, Japanese Section (2000, Osaka, Japan), **J Mol Cell Cardiol.** 2000;32:A93.
25. Difference in the Subcellular Actions of ACE Inhibitors and AT₁ Blockers on Attenuating Cardiac Hypertrophy Induced by Chronic Inhibition of Nitric Oxide Synthesis. **Sanada S**, Sata T, Sakata Y, Takashima S. The American Heart Association 74th Scientific Sessions (2001, Anaheim), **Circulation.** 2001;104:II-190.
26. The Selective Estrogen Receptor Modulator, Raloxifene, Reduces Infarct Size and Ventricular Arrhythmias in Canine Hearts. Ogita H, Kitakaze M, Node K, Asanuma H, **Sanada S**, Liao Y, Takashima S, Asakura M, Mori H, Shinozaki Y, Hori M. The American Heart Association 74th Scientific Sessions (2001, Anaheim), **Circulation.** 2001;104:II-150.
27. Ischemia-Selective Early Increase in Nitric Oxide Synthesis Confer Acute Cardioprotection Against Myocardial Infarction Afforded by Pravastatin. **Sanada S**, Kitakaze M, Asanuma H, Takashima S, Node K, Ogita H, Asakura M, Liao Y, Kuzuya T, Hori M. The American College of Cardiology 50th Annual Scientific Sessions (2001, Orlando), **J Am Coll Cardiol.** 2001; 37(Suppl A):363A.
28. Amelioration of Ischemia- and Reperfusion-Induced Myocardial Injury by Raloxifene: Roles of Nitric Oxide and the Opening of Calcium-Activated Potassium Channels. Ogita H, Kitakaze M, Node K, Asanuma H, **Sanada S**, Takashima S, Asakura M, Liao Y, Shinozaki Y, Mori H, Kuzuya T, Hori M. The American College of Cardiology 50th Annual Scientific Sessions (2001, Orlando), **J Am Coll Cardiol.** 2001; 37(Suppl A):363A. **J Am Coll Cardiol.** 2001; 37(Suppl A):362A.
29. The Dihydropyridine Ca Channel Blocker, Nifedipine, Limits Infarct Size via Bradykinin- and NO-Dependent Mechanisms in Dogs. Kitakaze M, Shinozaki Y, Mori H, Asanuma H, **Sanada S**, Asakura M, Ogita H, Liao Y, Takashima S, Kuzuya T, Hori M. The American College of Cardiology 50th Annual Scientific Sessions (2001, Orlando), **J Am Coll Cardiol.** 2001; 37(Suppl A):363A.

30. Heparin-Binding EGF-Like Growth Factor (HB-EGF) Plays a Critical Role in the EGFR Transactivation After Angiotensin II Stimulation in Vascular Smooth Muscle Cells. Asakura M, Kitakaze M, Takashima S, Higashiyama S, Asanuma H, **Sanada S**, Sakata Y, Ogita H, Liao Y, Toyofuku T, Kuzuya T, Tada M, Hori M. The American College of Cardiology 50th Annual Scientific Sessions (2001, Orlando), **J Am Coll Cardiol.** 2001; 37(Suppl A):270A.
31. A Novel Inhibitory Effect of Adenosine on Cardiac Hypertrophy. Asakura M, Kitakaze M, Takashima S, Higashiyama S, Sakata Y, Asanuma H, **Sanada S**, Ogita H, Liao Y, Node K, Toyofuku T, Kuzuya T, Tada M, Hori M. The American College of Cardiology 50th Annual Scientific Sessions (2001, Orlando), **J Am Coll Cardiol.** 2001; 37(Suppl A):272A.
32. Pravastatin Selectively Increases Coronary Blood Flow During Coronary Hypoperfusion Through the Activation of Nitric Oxide Synthesis. **Sanada S**, Asanuma H, Ogita H, Shintani Y, Liao Y, Minamino T, Kim J, Node K. The American Heart Association 75th Scientific Sessions (2002, Chicago), **Circulation.** 2002;106:II-13.
33. Rho-Kinase Inhibition as a Novel Mediator of Ischemic Preconditioning Independent of Protein Kinase C. **Sanada S**, Node K, Asanuma H, Ogita H, Ogai A, Minamino T, Takashima S, Fukushima T, Kim J, Shimokawa H, Hori M, Kitakaze M. The American Heart Association Scientific Conference on Molecular Mechanisms of Growth, Death, and Regeneration in the Myocardium (2003, Snowbird, UT)
34. **Sanada S**, Node K, Asanuma H, Ogita H, Liao Y, Shintani Y, Minamino T, Fukushima T, Ogai A, Kitakaze M. Preischemic Protein Kinase—A Activation Triggers Cardioprotection of Ischemic Preconditioning via the Inhibition of Rho—associated Kinase. The American Heart Association 76th Scientific Sessions (2003, Orlando), **Circulation.** 2003;108: IV-186.
35. Active LBP/p40 Retropseudogene Interacting with Heterochromatin Protein 1 Causes Right Ventricular Dysplasia. Asano Y, Takashima S, Asakura M, Shintani Y, Liao Y, Minamino T, **Sanada S**, Fukushima T, Hori M, Kitakaze M. The American Heart Association 76th Scientific Sessions (2003, Orlando), **Circulation.** 2003;108:IV-32.
36. Selective Serotonin 5HT_{2A} Receptor Inhibition Attenuates Coronary Ischemia Through the Increase in Nitric Oxide Production: The Alternative Role of 5HT_{1B} Receptor Activation. **Sanada S**, Kitakaze M, Node K, Asanuma H, Ogita H, Takashima S, Asakura M, Minamino T, Hori M. The American College of Cardiology 51th Annual Scientific Sessions (2002, Atlanta), **J Am Coll Cardiol.** 2002;39(Supple A):292A.
37. A New Development of High Fidelity Canine DNA Microarray: Application for the Assessment of Gene Expressions of Reversibly or Irreversibly Injured Ischemic Myocardium. Asakura M, Kitakaze M, **Sanada S**, Asanuma H, Takashima S, Minamino T, Node K, Ogita H, Asano Y, Shintani Y, Liao Y, Hori M. The American College of Cardiology 51th Annual Scientific Sessions (2002, Atlanta), **J Am Coll Cardiol.** 2002;39(Supple A):299A.
38. ACE Inhibitors and Angiotensin II Receptor Antagonists Independently but Synergistically Increase

Coronary Blood Flow and Attenuates the Severity of Contractile and Metabolic Dysfunction in Ischemic Hearts. Kitakaze M, Node K, Takashima S, Minamino T, Asanuma H, Asakura M, Kim J, **Sanada S**, Ogita H, Asano Y, Shintani Y, Hori M. The American College of Cardiology 51th Annual Scientific Sessions (2002, Atlanta), **J Am Coll Cardiol.** 2002;39(Supple A):288A.

39. Inhibitory Effects of Novel Antagonist of both GP I_{ib}/III_a and Vitronectin Receptors on the Formation of Coronary Thromboemboli Caused by an Inhibition of Adenosine Receptors During Coronary Hypoperfusion in Dogs. Asanuma H, Kitakaze M, Node K, **Sanada S**, Ogita H, Takashima S, Asakura M, Minamino T, Tada M, Hori M. The American College of Cardiology 51th Annual Scientific Sessions (2002, Atlanta), **J Am Coll Cardiol.** 2002;39(Supple A):300A.
40. Amlodipine Increases Coronary Blood Flow and Reduces the Severity of Myocardial Ischemia in Canine Hearts –Role of NO and Adenosine. Asanuma H, Kitakaze M, Node K, **Sanada S**, Ogita H, Takashima S, Asakura M, Minamino T, Tada M, Hori M. The American College of Cardiology 51th Annual Scientific Sessions (2002, Atlanta), **J Am Coll Cardiol.** 2002;39(Supple A):324A.
41. A Selective Estrogen Receptor Modulator, Raloxifene, Inhibits the Cardiac Hypertrophy and Dysfunction due to Aortic Banding in Mice. Ogita H, Kitakaze M, Node K, Takashima S, Asanuma H, Asakura M, **Sanada S**, Asano Y, Shintani Y, Hori M. The American College of Cardiology 52nd Annual Scientific Sessions (2003, Chicago), **J Am Coll Cardiol.** 2003;41(Supple A):228A.
42. Erythropoietin Enhances Neovascularization of Ischemic Myocardium and Improves Left Ventricular Dysfunction After Myocardial Infarction in Dogs. Hirata A, Minamino T, Asanuma H, **Sanada S**, Fujita M, Wakeno M, Nagamachi N, Takashima S, Asano Y, Hori M, Kitakaze M. The American Heart Association 78th Scientific Sessions (2005, Dallas), **Circulation.** 2005;112: II-199.
43. Nongenomic Effects of Aldosterone on Ischemic Hearts via PKC-dependent Pathways. Fujita M, Minamino T, Takashima S, Asanuma H, **Sanada S**, Hirata A, Wakeno M, Myoishi M, Okuda H, Hori M, Kitakaze M, Ogai A. The American Heart Association 78th Scientific Sessions (2005, Dallas), **Circulation.** 2005;112:II-28.
44. IL-33/ST2 is a Critical Cardioprotective Fibroblast-cardiomyocyte Signaling System Activated by Mechanical Overload. **Sanada S**, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. The American Heart Association 79th Scientific Sessions (2006, Chicago), **Circulation.** 2006;114: II-263.
45. Activation of A₁ Adenosine Receptors Inhibits the Adrenal Aldosterone Production and Attenuates Severity of Heart Failure. Tsukamoto O, Minamino T, **Sanada S**, Okazaki, H, Hisatome I, Takashima S, Shintani Y, Asano Y, Kitakaze, M. The American Heart Association 79th Scientific Sessions (2006, Chicago), **Circulation.** 2006;114: II-440.
46. IL-33 Reduces Cardiac Remodeling, Inhibits Myocardial Apoptosis and Improves Survival After Experimental Myocardial Infarction. **Sanada S**, Handa V, Hakuno D, Gannon J, McGillvray C, Lee RT. The American Heart Association 80th Scientific Sessions (2007, Orlando), **Circulation.** 2007;116: II-68.

47. Management of Hyperphosphatemia Is an Important Novel Therapeutic Target in Chronic Heart Failure. Asanuma H, Asakura M, Kim J, Takahama H, Sasaki H, **Sanada S**, Ohara T, Min K, Itou S, Fujita M, Asano Y, Takashima S, Minamino T, Komamura K, Kitakaze M. The American Heart Association 81st Scientific Sessions (2008, New Orleans), *Circulation*. 2008;118: S433.
48. Activation of Myocardial AMP-activated Protein Kinase by Metformin Prevents Progression of Heart Failure in Dogs; Involvement of eNOS Activation. Sasaki H, Asanuma H, Fujita M, Takahama H, Asakura M, Kim J, Minamino T, Takashima S, **Sanada S**, Itou S, Min K, Komamura K, Mochizuki N, Kitakaze M. The American Heart Association 81st Scientific Sessions (2008, New Orleans), *Circulation*. 2008;118: S286.
49. The effects of Angiotensin II receptor blockade on atrial late potential on paroxysmal atrial fibrillation with hypertension. Morita T, Yamada T, Okuyama Y, **Sanada S**, Furukawa Y, Masuda M, Iwasaki Y, Yasui T, Ueda H, Okada T, Kawasaki M, Fukunami M. The American Heart Association 81st Scientific Sessions (2008, New Orleans), *Circulation*. 2008;118:S829.
50. Usefulness of cardiac I-123 metaiodobenzylguanidine imaging for predictor of sudden cardiac death in chronic heart failure patients with mild to moderate systolic dysfunction. Ueda H, Yamada T, Okuyama Y, Morita T, **Sanada S**, Furukawa Y, Masuda M, Iwasaki Y, Yasui T, Okada T, Kawasaki M, Fukunami M. The American Heart Association 81st Scientific Sessions (2008, New Orleans), *Circulation*. 2008;118: S1067.
51. Clinical significance of serial studies of cardiac I-123 metaiodobenzylguanidine imaging for the predictor of sudden death in patients with chronic heart failure. Okada T, Yamada T, Okuyama Y, Morita T, **Sanada S**, Furukawa Y, Masuda M, Iwasaki Y, Yasui T, Ueda H, Kawasaki M, Fukunami M. The American Heart Association 81st Scientific Sessions (2008, New Orleans), *Circulation*. 2008;118: S1066.
52. Usefulness of Cardiac I-123 metaiodobenzylguanidine Imaging for Prediction of Cardiac Death in Heart Failure With/without Renal Dysfunction: A Prospective Study. Iwasaki Y, Yamada T, Okuyama Y, Morita T, **Sanada S**, Furukawa Y, Tsukamoto Y, Masuda M, Okuda K, Yasui T, Fukunami M. The American College of Cardiology 57th Annual Scientific Sessions (2008, Chicago), *J Am Coll Cardiol*. 2008;51(Suppl A):228A.
53. Intermittent Phosphodiesterase Type-3 Inhibition Reduces Inflammatory change, Restores Cardiac Remodeling and Prevents Progression of Heart Failure due to Depletion of Nitric Oxide Synthesis. **Sanada S**, Asanuma H, Tsukamoto O, Okada K, Fukunami M, Hori M, Kitakaze M. The European Society of Cardiology Heart Failure Congress 2008 (2008, Milan, Italy) *Eur J Heart Fail*. 2008;7 (Suppl 1):193.
54. Cardiac I-123 Metaiodobenzylguanidine Imaging Provides Additional Prognostic Power to Seattle Heart Failure Model in Patients With Chronic Heart Failure: A 10-year Follow-up Comparative Study. Kuramoto Y, Yamada T, Okuyama Y, Morita T, **Sanada S**, Furukawa Y, Tanaka K, Iwasaki Y, Yasui T, Ueda H, Kawasaki M, Okada T, Tamaki S, Levy WC, Fukunami M. The American Heart Association 82nd Scientific Sessions (2009, Orlando), *Circulation*. 2009;120: S861.

55. Iwasaki Y, Yamada T, Okuyama Y, Morita T, **Sanada S**, Furukawa Y, Masuda M, Yasui T, Ueda H, Okada T, Kawasaki M, Fukunami M. The Optimal Antithrombotic Therapy for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention With Stenting. The American College of Cardiology 58th Annual Scientific Sessions (2009, Orlando), **J Am Coll Cardiol**. 2009;53(Supple A):A429.
56. Effect of Vildagliptin on the improvement of survival in murine pressure-overload heart failure model. Takahashi A, Asakura M, Min KD, Ito S, Minamino T, Yan Y, Yamazaki S, **Sanada S**, Asanuma H, Liao Y, Takashima S, Mochizuki N, Kitakaze M. The American Heart Association 83rd Scientific Sessions (2010, Chicago), **Circulation**. 2010;122: A19013.
57. Anti-remodeling effects of adenosine via suppression of adrenal aldosterone production. Tsukamoto O, Fujita M, **Sanada S**, Kitakaze M, ISHR 20th World Congress (2010, Kyoto, Japan) **J Mol Cell Cardiol**. 2010.
58. Inhalation of hydrogen Gas Reduces Infarct Size via Mitochondrial KATP Channels in a Dog Model of Ischemia and Reperfusion Injury. Yoshida A, Asanuma H, Sasaki H, **Sanada S**, Yamazaki S, Takashima S, Minamino T, Asakura M, Kitakaze M. The Cardiovascular System Dynamics Society 19th International Congress (2010, Fukuoka, Japan)
59. Inhalation of hydrogen gas reduced infarct size following ischemia and reperfusion via mitochondrial KATP channels in canine hearts. Yoshida A, Asanuma H, Sasaki H, **Sanada S**, Yamazaki S, Takashima S, Minamino T, Asakura M, Kitakaze M. The European Society of Cardiology Congress 2010 (2010, Stockholm, Sweden) **Eur Heart J** 2010;31 (Suppl) :42.
60. Anti-remodeling effects of adenosine via suppression of adrenal aldosterone production. Tsukamoto O, Fujita M, **Sanada S**, Kitakaze M. The International Society for Heart Research 20th World Congress (2010, Kyoto, Japan) **J Mol Cell Cardiol**. 2010.
61. Yoshida A, Asanuma H, **Sanada S**, Yamazaki S, Takashima S, Minamino T, Asakura M, Mochizuki N, Kitakaze M. Inhaled hydrogen gas therapy reduced infarct size via mitochondrial KATP channels and mitochondrial permeability transition pore in a dog model of myocardial ischemia reperfusion injury. The European Society of Cardiology Congress 2011 (2011, Paris, France) **Eur Heart J** 2011;32(Suppl) :210.
62. Yoshida A, **Sanada S**, Asanuma H, Sasaki H, Takahama H, Asakura M, Yoshitomi T, Nagasaki Y, Kitakaze M. Novel synthesized radical-containing nanoparticles augment cardioprotection after ischemia-reperfusion injury via nitric oxide in canine hearts. The European Society of Cardiology Congress 2012 (2012, Munich, Germany) **Eur Heart J** 2012;33 (Suppl).
63. Development of New Trial Protocol Development Process Chart Using Quality by Design Method. Role of Adenosine in chronic heart failure: the possibility for novel therapeutic strategies. Matsuyama K, Iwasaki K, Nagao N, Matsushima Y, Hayashi H, **Sanada S**, Suzuki Y, Ozawa G, Yamaguchi T, Uemura N. The 18th World Congress of Basic and Clinical Pharmacology Congress (2018, Kyoto, Japan)

64. Japan's Advanced Medical Care Program for rapid introduction of unevaluated healthcare technologies toward National Health Insurance (NHI) coverage. **Sanada S**, Ueda K, Uemura N. The 18th World Congress of Basic and Clinical Pharmacology Congress (2018, Kyoto, Japan)
 65. Analysis of Core Competencies for the Clinical Data Management Profession in Japan. Takata M, Miyaji T, Hayashi Y, **Sanada S**, Yamaguchi T. The Society for Clinical Data Management 2020 Virtual Conference (2020, Sep 13-15, on the WEB)
-